147 related articles for article (PubMed ID: 27048413)
1. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
Ozawa Y; Akahori D; Koda K; Abe T; Hasegawa H; Matsui T; Tanahashi M; Niwa H; Yamada K; Yokomura K; Suda T
Cancer Chemother Pharmacol; 2016 May; 77(5):1031-8. PubMed ID: 27048413
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
3. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
4. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.
Tamiya A; Naito T; Miura S; Morii S; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Yamamoto N; Endo M
Anticancer Res; 2012 Mar; 32(3):1103-6. PubMed ID: 22399640
[TBL] [Abstract][Full Text] [Related]
6. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
7. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Kakiuchi S; Hanibuchi M; Tezuka T; Saijo A; Otsuka K; Sakaguchi S; Toyoda Y; Goto H; Kawano H; Azuma M; Ogushi F; Nishioka Y
Respir Investig; 2017 Mar; 55(2):145-152. PubMed ID: 28274530
[TBL] [Abstract][Full Text] [Related]
8. [A case of interstitial pneumonitis induced by S-1].
Ueyama Y; Yamamoto D; Yoshida H; Kanematsu S; Nakatake R; Kasahara N; Tanaka K; Shoji T; Okukawa H; Kwon AH
Gan To Kagaku Ryoho; 2010 Aug; 37(8):1603-6. PubMed ID: 20716897
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
[TBL] [Abstract][Full Text] [Related]
10. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
12. [A case of interstitial pneumonia after S-1 administration for gastric cancer].
Yamamoto N; Ohshima T; Sato T; Makino H; Kanazawa A; Yamada T; Murakami H; Yukawa N; Nagano Y; Fujii S; Kunisaki C; Tsukahara T; Rino Y; Masuda M; Imada T
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1935-7. PubMed ID: 19011347
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
14. Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer.
Ozawa Y; Abe T; Omae M; Matsui T; Kato M; Hasegawa H; Enomoto Y; Ishihara T; Inui N; Yamada K; Yokomura K; Suda T
PLoS One; 2015; 10(10):e0140437. PubMed ID: 26460792
[TBL] [Abstract][Full Text] [Related]
15. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
16. Severe interstitial lung disease associated with amrubicin treatment.
Yoh K; Kenmotsu H; Yamaguchi Y; Kubota K; Ohmatsu H; Goto K; Niho S; Ohe Y; Saijo N; Nishiwaki Y
J Thorac Oncol; 2010 Sep; 5(9):1435-8. PubMed ID: 20683210
[TBL] [Abstract][Full Text] [Related]
17. [A case of drug-induced interstitial pneumonia caused by S-1 and CPT-11 combination therapy for advanced colon cancer].
Kuga Y; Tanaka T; Okanobu H; Arita M; Yoshimi S; Miwata T; Fujino H; Moriya T; Ohya T
Gan To Kagaku Ryoho; 2011 Mar; 38(3):469-72. PubMed ID: 21403457
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease associated with docetaxel in a patient treated for breast cancer - a case report.
Pankowska-Supryn M; Załęska M; Roszkowska-Śliż B; Roszkowski-Śliż K
Pneumonol Alergol Pol; 2015; 83(5):378-82. PubMed ID: 26378999
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
